Monday, October 3, 2022
News
NEWS HOME
»
PRN INDIA
Merck Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform
  SocialTwist Tell-a-Friend  
   

  • Reduces process development time by an estimated 40 percent
  • Enables biopharmaceutical companies to increase the speed to clinical manufacturing
  • Adds to company's best-in-class VirusExpress ® Lentiviral Production Platform

DARMSTADT, Germany, Aug. 9, 2022 /PRNewswire/ --  Merck, a leading science and technology company, has launched the VirusExpress ® 293 Adeno-Associated Virus (AAV) Production Platform, making it one of the first CDMOs and technology-developers to provide a full viral vector manufacturing offering including AAV, Lentiviral, CDMO, CTO, and process development. This new platform enables biopharmaceutical companies to increase the speed to clinical manufacturing while reducing process development time and costs.

Merck scientists operating a 200 L Mobius ® Single-Use Bioreactor using the VirusExpress ® 293 Adeno-Associated Virus Production Platform at the company's facility in Carlsbad, California.

"Cell and gene therapies offer the potential for curative treatments and can be commercialized in half the time compared to traditional therapies," said Dirk Lange, Head of Life Science Services, Life Science business sector at Merck. "By increasing dose yields and dramatically reducing process development time, our VirusExpress ® 293 AAV Production Platform will accelerate manufacturing of these therapies, ultimately delivering lifesaving treatments to patients faster."

The new platform is an extension of the company's VirusExpress ® offering, which can reduce process development time by up to 40 percent, based on Merck's experience as a CDMO. The company's VirusExpress ® Lentiviral Production Platform has enabled customers to increase the speed to clinical manufacturing, achieve five times higher titer than the leading competitor, and transition a legacy process to a templated solution.

Merck's VirusExpress ® Platforms offer a simplified upstream workflow for the production of AAV and Lentivirus, making processes easier to manage, adjust and scale. In addition to accelerating process development, the suspension culture format allows for larger batch yields to enable more patient doses. Additionally, suspension culture is amenable to scalable robust manufacturing processes, while being less labor-intensive. The chemically defined cell culture media eliminates the safety, regulatory and supply chain concerns related to animal- and human-derived materials. Flexible licensing allows companies to manufacture vectors by using Merck's contract manufacturing capabilities and expertise with access to both the upstream and downstream templates or by using in-house development or a third-party.

The Life Science business sector of Merck is a leading CDMO and has been involved in this space since clinical trials for gene therapy began in the 1990s. In October 2021, the company opened its second Carlsbad, California-based facility, more than doubling its existing production capacity to support large-scale commercial manufacturing.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 60,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck generated sales of € 19.7 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

Photo - https://mma.prnewswire.com/media/1874155/Merck_VirusExpress.jpg

More News by PR Newswire India

FANDOM ACQUIRES LEADING ENTERTAINMENT & GAMING BRANDS INCLUDING GAMESPOT, TV GUIDE AND METACRITIC

National Engineering Industries Ltd (NBC Bearings) honored with 'Iconic Brands of India 2022'

Celebrating Glorious 35 Years of BIMTECH

HABANOS, S.A. PRESENTED THE MONTECRISTO WIDE EDMUNDO IN WORLD PREMIERE IN SPAIN

Sanjay Ghodawat Foundation awarded The Mahatma Award 2022

STL announces Gram Galaxy - India's first integrated solution to connect villages with fibre

DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY

Healthium Medtech amongst the first in Asia and first Indian Medtech Company to receive CE certification under the EU MDR (European Union Medical Device Regulation) norms for Class III implants

Jagadguru Kripalu Parishat holds Grand Rath Yatra on 3rd October 2022 near Kunda, Pratapgarh in honor of the 100th Birth Anniversary of Jagadguru Shri Kripalu Ji Maharaj

Addteq APAC Announces Rebranding, Changes Name to Enreap

Karwa Chauth 2022: FlowerAura Is All Geared Up To Enhance The Celebrations

DMCC AWARDED GLOBAL FREE ZONE OF THE YEAR FOR EIGHTH CONSECUTIVE YEAR

New Book Property Tax in Asia Provides the First Comprehensive Analysis of the Property Tax Across the World's Largest Continent

UN WOMEN'S HeForShe EXPANDS MOVEMENT THROUGH KEY PUBLIC AND PRIVATE PARTNERSHIPS IN EAST ASIA

STL unveils 5G cosmos to help Indian telcos fiberise their networks for 5G

STL launches Multiverse - India's first Multicore fibre and cable; aims to revolutionize the optical landscape

Tejas Networks successfully demonstrates end-to-end network based on its indigenous 4G/5G wireless, optical and satellite products

IIIT Hyderabad and Silicon Labs Launch Campus-wide Wi-SUN Network for Smart City Applications

STL unveils 5G cosmos to help Indian telcos fiberise their networks for 5G

STL launches Multiverse - India's first Multicore fibre and cable; aims to revolutionize the optical landscape

Tejas Networks successfully demonstrates end-to-end network based on its indigenous 4G/5G wireless, optical and satellite products

IIIT Hyderabad and Silicon Labs Launch Campus-wide Wi-SUN Network for Smart City Applications

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Mumbai Congress leader, 'Mummy' of Colab...
Durga Puja pandal fire in Uttar Pradesh'...
7-yr-old dies after electric scooter's b...
3 dead in Durga Puja pandal fire in UP's...
Navratri 2022: Maha Ashtami today, devot...
Made-In-India Light Combat Helicopter to...
More...    
 
 Top Stories
Nadda inspects arrangements for PM ... 
Shashi Tharoor highlights need for ... 
83 per cent of women have visited a... 
"No need to define 'Prachand', mess... 
Taiwan disapproves of China's false... 
World Team TT Championships: Indian... 
Mumbai: Man dies after chest pain w... 
Barmer girl rape: Accused arrested ...